skip to Main Content

Performance Status Key to Treatment for Pancreas Adenocarcinoma

Newsfeed image, light gray text on dark gray background
Choosing between the two effective front-line regimens for patients with advanced pancreas adenocarcinoma who have good performance status is a challenge.

Both FOLFIRINOX (fluorouracil, irinotecan, and oxaliplatin) and gemcitabine plus nab-paclitaxel have been proven active in this disease, but have not been compared head-to-head in first line treatment.

The relative merits of each as initial therapy were discussed at the European Society of Medical Oncology World Congress on Gastrointestinal Cancer by Eileen M. O’Reilly, MD, Associate Director, Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, and Professor of Medicine, Weill Cornell Medical College. Read more . . .

Back To Top